PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems(Centre National de la Recherche Scientifique), Didier Bouscary(Centre National de la Recherche Scientifique), Jérôme Tamburini(University of Geneva), Patrick Mayeux(Université Paris Cité), Nicolas Chapuis(Délégation Paris 5), Catherine Lacombe(Centre National de la Recherche Scientifique)
Cited by 210
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
|Blood|2015|383
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
|Haematologica|2009|316